Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning, and welcome to Johnson & ...

Johnson has also claimed that the Great Depression was "pretty well planned," adding he knew it sounds like a conspiracy theory. In his interview with Benny Johnson, the senator said he knew they ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations ...

with James Austin Johnson's take on the president predicting that his plan would "Make America Great Depression Again." The sketch served as a showcase for Johnson's discursive and oddly inflected ...

Selma Blair spoke very candidly to PEOPLE about her health following her multiple sclerosis diagnosis while attending The ...

Probiotics may help improve a person's daily mood and, if taken regularly for about 2 weeks, could help reduce negative ...

Child diagnoses are rising; however, due to changing definitions, systems, and expectations, it is not an epidemic of illness ...

a treatment for bipolar disorder and depression. Management said they now expect sales of $92 billion this year, up from a previous forecast of $91.3 billion. Johnson & Johnson’s cash flow.

Further, it provides a sense of dignity and self-worth for patients by giving them a sense of making a valuable contribution.